Osprey Private Wealth LLC Has $1.36 Million Stock Position in Eli Lilly and Company $LLY

Osprey Private Wealth LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 243.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,780 shares of the company’s stock after acquiring an additional 1,261 shares during the period. Osprey Private Wealth LLC’s holdings in Eli Lilly and Company were worth $1,358,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Armstrong Advisory Group Inc. boosted its holdings in shares of Eli Lilly and Company by 53.6% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 8,770 shares of the company’s stock valued at $6,691,000 after buying an additional 3,062 shares during the last quarter. Fiduciary Alliance LLC increased its holdings in Eli Lilly and Company by 3.1% during the third quarter. Fiduciary Alliance LLC now owns 10,571 shares of the company’s stock worth $8,066,000 after buying an additional 318 shares during the last quarter. Cox Capital Mgt LLC raised its position in Eli Lilly and Company by 0.5% during the third quarter. Cox Capital Mgt LLC now owns 4,983 shares of the company’s stock worth $3,802,000 after acquiring an additional 23 shares in the last quarter. RDA Financial Network lifted its stake in Eli Lilly and Company by 4.2% in the third quarter. RDA Financial Network now owns 3,255 shares of the company’s stock valued at $2,484,000 after acquiring an additional 131 shares during the last quarter. Finally, Pinnacle Wealth Management Group Inc. acquired a new stake in Eli Lilly and Company in the third quarter valued at $249,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY stock opened at $1,056.57 on Friday. The company’s 50-day moving average price is $956.00 and its two-hundred day moving average price is $828.10. The firm has a market cap of $998.86 billion, a P/E ratio of 51.69, a P/E/G ratio of 1.31 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Wolfe Research raised their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. HSBC reaffirmed a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 10th. UBS Group reissued a “neutral” rating on shares of Eli Lilly and Company in a report on Thursday. Finally, Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,141.73.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.